

DISCLAIMER

The following is a preliminary report of actions taken by the House of Delegates at its 2025 Interim Meeting and should not be considered final. Only the Official Proceedings of the House of Delegates reflect official policy of the Association.

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (I-25)

Final Report of Reference Committee K

Samuel Huang, MD, Chair

1 RECOMMENDED FOR ADOPTION

- 2
- 3 1. *BOT 24 - Amending Vaccine-Related Policies
- 4 2. Resolution 901 - Distinction Between Healthful and Unhealthful "Ultraprocessed"
- 5 Foods
- 6 3. Resolution 920 - Alcohol and Aging: Educating Physicians and Advocating for
- 7 Safer Warnings
- 8 4. Resolution 922 - Addressing Health Impacts of Indian Boarding Schools
- 9 5. Resolution 923 - Enhancing Disaster Preparedness Mechanisms for People with
- 10 Disabilities
- 11 6. Resolution 924 - Preserving Access to Gamete Donation and Gestational
- 12 Carriers and Protecting Parental Rights
- 13 7. Resolution 926 - Establishment of Federal and State Offices of Men's Health
- 14 8. Resolution 929 - Protecting Access to Evidence-base Psychotropic Medications
- 15 for the Treatment of Pediatric Mental Illness
- 16 9. Resolution 932 - Shared Decision-Making and Low Dose CT Lung Cancer
- 17 Screening in Clinical Practice
- 18

19 RECOMMENDED FOR ADOPTION AS AMENDED

- 20
- 21 10. *CSAPH 02 - Regulation of Ionizing Radiation Exposure for Health Care
- 22 Professionals
- 23 11. CSAPH 03 - Plastic Pollution Reduction
- 24 12. *Resolution 902 - Advocating For Improvements in Systems of Care for Autism
- 25 13. Resolution 905 - Standardizing Brain Death Policies
- 26 14. Resolution 907- In-Office Dispensing of Generic Medications
- 27 15. *Resolution 909 - Clinical Significance of Sleepiness
- 28 16. Resolution 911- Safeguarding NIH-Funded and Other Women's Health Research
- 29 in Peer-Reviewed Publishing
- 30 17. Resolution 912 - Increasing Access through Federated Healthcare Data
- 31 Architecture
- 32 18. Resolution 933 - Addressing Gaps in National Healthcare Safety Network
- 33 (NHSN) Data Quality
- 34 19. *Resolution 935 - Enhancing Healthcare System Preparedness to Address
- 35 Veteran-Specific Health Disparities

1 **RECOMMENDED FOR ADOPTION IN LIEU OF**

- 2
3 20. Resolution 931 - Preserving Evidence-Based, Equitable Grooming Standards in
4 Military Service

5 **RECOMMENDED FOR REFERRAL**

- 6
7 21. Resolution 906 - Rethinking the Medicare Annual Wellness Visit
8 22. *Resolution 917 - Urging Comprehensive Research and Safety Testing of
9 Industry-Engineered Food Additives (IEFAs), Including High Fructose Corn Syrup
10 23. Resolution 918 - Remove Outdated Barriers to Genetic Testing
11 24. *Resolution 921 - Prioritizing Deprescribing Seniors
12 25. *Resolution 927 - Battlefield Acupuncture - An Educational Call to Arms
13 26. Resolution 930 - Establishing Fire Risk Standards for Civilian and Non-Industrial
14 Clothing

15
16 **RECOMMENDED FOR REFERRAL FOR DECISION**

- 17
18 27. *Resolution 919 - Strengthening Trust through AMA-Based Leadership for
19 Evidence-Based Vaccines (STABLE Vaccines)
20 Resolution 925 - Evidence-Based Vaccine and Preventive Services
21 Recommendation
22

23 **RECOMMENDED FOR NOT ADOPTION**

- 24
25 28. Resolution 904 - Supporting Certification of the Public Health Workforce
26 29. Resolution 908 - Support of Access to Insulin-Detemir
27

28 **RECOMMENDED FOR REAFFIRMATION IN LIEU OF**

- 29
30 30. Resolution 903 - Nitrous Oxide Inhalant Abuse

*Your Reference Committee recommendation has changed from the Preliminary Report

RECOMMENDED FOR ADOPTION

1
2 (1) BOT 24 - AMENDING VACCINE-RELATED POLICIES
3

4 **RECOMMENDATION:**
5

6 **Your Reference Committee recommends that the Board**
7 **of Trustees Report 24 be adopted.**
8

9 **HOD ACTION: BOT 24 adopted and the remainder of the Report filed.**
10

11
12 The Board of Trustees recommends that the House of Delegates policies listed in the
13 appendix to this report be acted upon in the manner indicated and the remainder of this
14 report be filed. (Directive to Take Action)
15

16 Your Reference Committee heard unanimously supportive testimony for this item. Multiple
17 delegations testified in favor of the report. A delegation emphasized that medical specialty
18 recommendations are important, especially given the multiple concurrent initiatives at the
19 state level. Another delegation highlighted the importance of maintaining scientific
20 evidence as the highest priority. Your Reference Committee agrees with these points and;
21 therefore, your Reference Committee recommends that the report's recommendations be
22 adopted.
23

24 (2) RESOLUTION 901 - DISTINCTION BETWEEN
25 HEALTHFUL AND UNHEALTHFUL "ULTRAPROCESSED"
26 FOODS
27

28 **RECOMMENDATION:**
29

30 **Your Reference Committee recommends that**
31 **Resolution 901 be adopted.**
32

33 **HOD ACTION: Resolution 901 adopted.**
34

35
36 RESOLVED, that our American Medical Association encourage public education on the
37 difference between healthful "ultraprocessed" foods and unhealthy "ultraprocessed"
38 foods (New HOD Policy); and be it further
39

40 RESOLVED, that our AMA amend AMA policy H-150.914, Addressing the Health Impacts
41 of Ultraprocessed Foods, by deletion to remove the first appearance of the word "food,"
42 so as to read "Our AMA supports and promotes public awareness and education about
43 the differences between healthful ~~foods~~ and unhealthy ultraprocessed foods (UPF) and
44 the benefits of minimally processed and unprocessed foods." (Modify Current HOD Policy)

1 Your Reference Committee heard testimony that was largely supportive of this resolution.
2 Current AMA policy assumes that all ultra-processed foods are unhealthy, but as noted
3 in testimony there are some foods classified as ultra-processed food that have health
4 benefits. This proposed amendment better aligns AMA policy with current evidence. There
5 was some concern that there is no standard definition of ultra-processed foods, but that
6 work is being undertaken and is beyond the scope of this resolution. Therefore, your
7 Reference Committee recommends that Resolution 901 be adopted.

8
9 (3) RESOLUTION 920 - ALCOHOL AND AGING:
10 EDUCATING PHYSICIANS AND ADVOCATING FOR
11 SAFER WARNINGS

12
13 **RECOMMENDATION:**

14
15 **Your Reference Committee recommends that**
16 **Resolution 920 be adopted.**

17
18 **HOD ACTION: Resolution 920 adopted.**

19
20
21 **RESOLVED**, that our American Medical Association advocate for the inclusion of clear,
22 evidence-based warnings concerning the health risks of alcohol use in seniors on all
23 alcoholic beverage containers, and work with regulatory bodies to develop standards for
24 such warning labels in alignment with AMA policy. (Directive to Take Action)

25
26 Your Reference Committee heard unanimously supportive testimony on this resolution,
27 with many dementia specialists and geriatric practitioners noting a need for greater
28 awareness around the harmful effects of alcohol on aged populations. Therefore, your
29 Reference Committee recommends that Resolution 920 be adopted.

30
31 (4) RESOLUTION 922 - ADDRESSING HEALTH IMPACTS OF
32 INDIAN BOARDING SCHOOLS

33
34 **RECOMMENDATION:**

35
36 **Your Reference Committee recommends that**
37 **Resolution 922 be adopted.**

38
39 **HOD ACTION: Resolution 922 adopted.**

40
41
42 **RESOLVED**, that our American Medical Association support efforts to address the
43 historical injustices and ongoing health impacts of Indian boarding schools. (New HOD
44 Policy)

1 Your Reference Committee heard mostly supportive testimony for Resolution 922. Multiple
2 delegations/sections in support noted the importance of addressing the ongoing health
3 harms of Indian boarding schools and their resultant health disparities. Testimony in
4 support also noted that physicians must acknowledge the historical harms that continue
5 to manifest in the bodies, minds, and communities of Indigenous patients and
6 communities. Two individuals in opposition noted that this resolution is out of scope of the
7 AMA's advocacy efforts. Given that the majority of the testimony was in support of this
8 resolution, your Reference Committee recommends that Resolution 922 be adopted.

9
10 (5) RESOLUTION 923 - ENHANCING DISASTER
11 PREPARADNESS MECHANISMS FOR PEOPLE WITH
12 DISABILITIES

13
14 **RECOMMENDATION:**

15
16 **Your Reference Committee recommends that**
17 **Resolution 923 be adopted.**

18
19 **HOD ACTION: Resolution 923 adopted.**

20
21
22 RESOLVED, that our American Medical Association, in coordination with relevant
23 stakeholders, advocate for greater integration of inclusive emergency alert systems (e.g.,
24 visual, auditory, and haptic notifications) in emergency preparedness planning to ensure
25 disaster response accessibility for people with disabilities (Directive to take Action); and
26 be it further

27
28 RESOLVED, that our AMA support increased federal and state funding for disability-
29 specific disaster preparedness measures such as assistive technologies, durable medical
30 equipment, mobility devices, and education programs in collaboration with relevant
31 stakeholders. (New HOD Policy

32
33 Your Reference Committee heard unanimous testimony in support of adopting resolution
34 923 and in opposition to reaffirmation. Multiple delegations/sections in support of adoption
35 noted that this resolution builds upon existing AMA policy by providing specific and
36 critically needed inclusive language that advocates for disaster preparedness that is
37 tailored to our disabled population. A delegation proffered an amendment to delete
38 " increased federal and state funding for" in the second Resolved clause noting that early
39 responders such as the Red Cross and other local agencies are funded by donations and
40 fundraising so the request for federal and state dollars is not beneficial. Given that the
41 majority of the testimony by multiple delegations/sections was in support of including
42 language about increasing federal and state funding, your Reference Committee
43 recommends that Resolution 923 be adopted.

1 (6) RESOLUTION 924 - PRESERVING ACCESS TO GAMETE
2 DONATION AND GESTATIONAL CARRIERS AND
3 PROTECTING PARENTAL RIGHTS
4

5 **RECOMMENDATION:**
6

7 **Your Reference Committee recommends that**
8 **Resolution 924 be adopted.**
9

10 **HOD ACTION: Resolution 924 adopted.**
11

12
13 RESOLVED, that our American Medical Association support policies and initiatives that
14 protect, standardize, and improve access to gamete donation and gestational carrying as
15 recognized options for assisted reproduction (New HOD Policy); and be it further
16

17 RESOLVED, that our AMA support efforts by appropriate parties to provide resources for
18 intended parents, gestational carriers, gamete donors, and children born with the aid of
19 gamete donation and/or gestational carrying (New HOD Policy); and be it further
20

21 RESOLVED, that our AMA advocates for accessibility, timeliness, and dignity in the
22 process of establishing parentage for children born from gamete donation and/or
23 gestational carrying. (Directive to Take Action)
24

25 Your Reference Committee heard strong support from multiple delegations. Two
26 delegations highlighted that Resolution 924 is in strong alignment with existing policy
27 including Policy 4.2.1 (Assisted Reproductive Technology), 4.2.2 (Gamete Donation), and
28 4.2.4 (Third-Party Reproduction). Moreover, it builds upon AMA's long-standing
29 commitment to ethical, inclusive, and evidence-based reproductive care. A handful of
30 individuals opposed the resolution as unethical, racist, ableist, and sexist. Given the
31 alignment with existing policy and strong section and delegation support, your Reference
32 Committee recommends Resolution 924 be adopted.
33

34 (7) RESOLUTION 926 - ESTABLISHMENT OF FEDERAL
35 AND STATE OFFICES OF MEN'S HEALTH
36

37 **RECOMMENDATION:**
38

39 **Your Reference Committee recommends that**
40 **Resolution 926 be adopted.**
41

42 **HOD ACTION: Resolution 926 adopted.**
43

44 **ADOPTED LANGUAGE:**

45 **Policy D-160.985 "Establishment of Federal and State Offices of Men's Health"**
46

47 **1. Our AMA encourages the establishment of an Office of Men's Health within the**
48 **federal Department of Health and Human Services to coordinate awareness,**
49 **outreach, and outcomes on men's health.**

1 **2. Our AMA encourages the establishment of an Office of Men's Health within**
2 **each state's Department of Health and Human Services to coordinate awareness,**
3 **outreach, and outcomes on men's health.**
4

5
6 RESOLVED, that our American Medical Association amend Policy D-160.985,
7 Establishment of an Office of Men's Health, to read as follows:
8

9 **Establishment of an Federal and State Offices of Men's Health**

10
11 1. Our AMA encourages the establishment of an Office of Men's Health at the U.S. within
12 the federal Department of Health and Human Services to coordinate awareness, outreach,
13 and outcomes on men's health.

14
15 2. Our AMA encourages the establishment of an Office of Men's Health within each state's
16 Department of Health and Human Services to coordinate awareness, outreach, and
17 outcomes on men's health. (Modify Current HOD Policy)
18

19 Your Reference Committee heard unanimously supportive testimony in favor of this
20 resolution, with many delegations and sections noting the timeliness of this policy as
21 suicide rates among men have continued to climb. Therefore, your Reference Committee
22 recommends resolution 926 be adopted.
23

24 (8) RESOLUTION 929 - PROTECTING ACCESS TO
25 EVIDENCE-BASE PSYCHOTROPIC MEDICATIONS FOR
26 THE TREATMENT OF PEDIATRIC MENTAL ILLNESS
27

28 **RECOMMENDATION:**

29
30 **Your Reference Committee recommends that**
31 **Resolution 929 be adopted.**
32

33 **HOD ACTION: Resolution 929 adopted.**
34

35
36 RESOLVED, that our American Medical Association opposes limitations on access to
37 psychotropic medication as part of a comprehensive mental health treatment plan (New
38 HOD Policy); and be it further
39

40 RESOLVED, that our AMA advocates that the U.S. Department of Health and Human
41 Services and Congress use peer reviewed pediatric mental health research, and evidence
42 based clinical guidelines developed by non-profit medical professional societies to inform
43 pediatric mental health policy. (Directive to Take Action)

1 Your Reference Committee heard testimony that was unanimously supportive of this
2 resolution. In particular, there was concern for politicalization and misinformation limiting
3 the access for critical mental health treatment in pediatric patients, noting that this specific
4 resolution advocates with the detailed policy needed to support evidence-based
5 treatment. Therefore, your Reference Committee recommends Resolution 929 be
6 adopted.

7
8 (9) RESOLUTION 932 - SHARED DECISION-MAKING AND
9 LOW DOSE CT LUNG CANCER SCREENING IN
10 CLINICAL PRACTICE

11
12 **RECOMMENDATION:**

13
14 **Your Reference Committee recommends that**
15 **Resolution 932 be adopted.**

16
17 **HOD ACTION: Resolution 932 adopted.**

18
19
20 **RESOLVED**, that our American Medical Association, in conjunction with other interested
21 national specialty societies of expertise (e.g., ACP, AAFP, ACR, etc.), create and share
22 educational resources and training to help physicians efficiently discuss and document
23 low-dose computed tomography (LDCT) lung cancer screening during shared decision-
24 making visits for high-risk populations. (Directive to Take Action)

25
26 Your Reference Committee heard testimony from three delegations and one individual in
27 support of adopting Resolution 932, therefore your Reference Committee recommends
28 adoption of Resolution 932

1 **RECOMMENDED FOR ADOPTION AS AMENDED**

2
3 (10) CSAPH 02 REGULATION OF IONIZING RADIATION
4 EXPOSURE FOR HEALTH CARE PROFESSIONALS

5
6 **RECOMMENDATION A:**

7
8 Your Reference Committee recommends that the
9 Recommendation in the Council on Science and Public
10 Health (CSAPH) Report 2 be amended by addition and
11 deletion to read as follows:

12
13 Policy H-455.975, “Regulation of Ionizing Radiation
14 Exposure for Health Care Workers” be amended by
15 addition and deletion to read as follows:

16
17 1. Our American Medical Association encourages: (1)
18 public and private health care institutions to ensure the
19 availability of personal protective equipment (PPE) that
20 provides comprehensive coverage of different body
21 types by providing readily available PPE that reduces to
22 reduce ionizing radiation exposure to as low as
23 reasonably achievable for employees health care
24 personnel and trainees of all genders and pregnancy
25 statuses; (2) the use of dosimetry badges for all
26 employees health care personnel and trainees who work
27 in exposure-prone settings, with clear follow-up actions
28 for those with elevated cumulative exposure; (3)
29 continued research on the health effects of low level and
30 very-low level exposure to ionizing radiation, the
31 effectiveness of PPE and administrative and engineering
32 controls designed to reduce exposure (e.g., shielding,
33 interlock systems, labeling,), barriers to PPE use (e.g.,
34 fit, availability, cost), and ways to improve PPE use
35 fidelity (e.g., training, education, and access to
36 appropriately sized and ergonomic PPE); ~~and~~ (4)
37 education for all health care personnel, including
38 trainees, and trainees specific to their expected
39 exposure exposed to ionizing radiation that includes
40 awareness of and methods to limit radiation exposure to
41 both patients and clinicians; and (5) collaboration
42 between medical specialty societies to establish
43 education and training standards for the use of PPE and
44 engineering controls to reduce exposure to ionizing
45 radiation for health care personnel and trainees.
46 ~~Training programs should provide education specific to~~
47 ~~their specialties so trainees know which protective~~
48 ~~equipment and controls their facilities should have in~~
49 ~~place and know how to use them correctly.~~

1 ~~2. Our AMA will work with the appropriate and interested~~
2 ~~parties to study how best to accomplish comprehensive~~
3 ~~protection from ionizing radiation for employees, taking~~
4 ~~into account variation in body types, pregnancy status,~~
5 ~~specifics of procedures being performed, as well as how~~
6 ~~exposure can be limited beyond PPE (personal~~
7 ~~protected equipment), with report back at I-25.~~

8
9 **RECOMMENDATION B:**

10
11 Your Reference Committee recommends that the
12 Recommendation in the Council on Science and Public
13 Health (CSAPH) Report 2 adopted as amended and the
14 remainder of the report be filed.

15
16 **HOD ACTION: CSAPH Report 2 adopted as amended and remainder of Report**
17 **filed.**

18
19 **ADOPTED LANGUAGE:**

20 **Policy H-455.975, "Regulation of Ionizing Radiation Exposure for Health Care**
21 **Workers"**

22
23 **1. Our American Medical Association encourages: (1) public and private health**
24 **care institutions to ensure the availability of personal protective equipment (PPE)**
25 **that provides comprehensive coverage of different body types to reduce ionizing**
26 **radiation exposure to as low as reasonably achievable for health care personnel**
27 **and trainees of all genders and pregnancy statuses; (2) the use of dosimetry**
28 **badges for all health care personnel and trainees who work in exposure-prone**
29 **settings, with clear follow-up actions for those with elevated cumulative exposure;**
30 **(3) continued research on the health effects of low level and very-low level**
31 **exposure to ionizing radiation, the effectiveness of PPE and administrative and**
32 **engineering controls designed to reduce exposure (e.g., shielding, interlock**
33 **systems, labeling,), barriers to PPE use (e.g., fit, availability, cost), and ways to**
34 **improve PPE use fidelity (e.g., training, education, and access to appropriately**
35 **sized and ergonomic PPE); (4) education for all health care personnel and trainees**
36 **specific to their expected exposure to ionizing radiation that includes awareness**
37 **of and methods to limit radiation exposure to both patients and clinicians; and (5)**
38 **collaboration between medical specialty societies to establish education and**
39 **training standards for the use of PPE and engineering controls to reduce**
40 **exposure to ionizing radiation for health care personnel and trainees.**

41
42
43 Your Council on Science and Public Health recommends that the following be adopted
44 and the remainder of this report be filed.

45
46 That Policy H-455.975, "Regulation of Ionizing Radiation Exposure for Health Care
47 Workers" be amended by addition and deletion to read as follows:
48

- 1 1. Our American Medical Association encourages: (1) public and private health care
2 institutions to ensure the availability of personal protective equipment (PPE) that
3 provides comprehensive coverage of different body types by providing readily
4 available PPE that reduces to reduce ionizing radiation exposure to as low as
5 reasonably achievable for employees and trainees of all genders and pregnancy
6 statuses; (2) continued research on the health effects of low level and very-low
7 level ionizing radiation, the effectiveness of PPE and administrative and
8 engineering controls designed to reduce exposure (e.g., shielding, interlock
9 systems, labeling,), barriers to PPE use (e.g., fit, availability, cost), and ways to
10 improve PPE use fidelity (e.g., training, education, and access to appropriately
11 sized and ergonomic PPE), and (3) education for all health care personnel,
12 including trainees, exposed to ionizing radiation that includes awareness of and
13 methods to limit radiation exposure to both patients and clinicians. Training
14 programs should provide education specific to their specialties so trainees know
15 which protective equipment and controls their facilities should have in place and
16 know how to use them correctly.
- 17
18 2. ~~Our AMA will work with the appropriate and interested parties to study how best to~~
19 ~~accomplish comprehensive protection from ionizing radiation for employees,~~
20 ~~taking into account variation in body types, pregnancy status, specifics of~~
21 ~~procedures being performed, as well as how exposure can be limited beyond PPE~~
22 ~~(personal protected equipment), with report back at I-25.~~

23
24 Your Reference Committee heard testimony in strong support of the report's
25 recommendations from multiple delegations and sections. Three amendments were
26 proposed. The first amendment suggested adding "sexes" to the first recommendation, so
27 it would read "...and trainees of all sexes, genders, and pregnancy statuses." However,
28 this addition was not supported by other testimony. The two remaining amendments
29 received unanimous support. One delegation proposed adding language to advocate for
30 routine radiation monitoring using dosimetry badges for all employees and trainees who
31 work in exposure-prone settings. Another section recommended changing the language
32 from "employees and trainees" to "health care personnel and trainees" to better include
33 non-clinician employees. They also proposed revising the last clause to state:
34 "collaboration between medical specialty societies to establish education and training
35 standards for the use of PPE and engineering controls to reduce exposure to ionizing
36 radiation for health care personnel and trainees." Testimony submitted through the online
37 Reference Committee was also supportive of the report's recommendations. Given the
38 strong support for the latter two amendments and supportive online testimony, your
39 Reference Committee recommends that the report's recommendation be adopted as
40 amended.

1 (11) CSAPH 03 - PLASTIC POLLUTION REDUCTION

2
3 **RECOMMENDATION A:**

4
5 Your Reference Committee recommends that the
6 second Recommendation in CSAPH 3 be amended by
7 addition and deletion to read as follows:
8

9 2. That Policy D-135.976, “Modernization of the Federal
10 Toxic Substances Control Act (TSCA) of 1976” be
11 amended by addition and deletion to read as follows:
12

13 Our AMA will: (1) collaborate with relevant stakeholders
14 to advocate for modernizing the Toxic Substances
15 Control Act (TSCA) to require chemical manufacturers
16 to provide adequate safety information on all chemicals
17 and give federal regulatory agencies reasonable
18 authority to regulate hazardous chemicals in order to
19 protect the health of all individuals, especially
20 vulnerable populations; (2) support the public
21 disclosure of chemical use, exposure and hazard data
22 in forms that are appropriate for use by medical
23 practitioners, workers, and the public; (3) encourage
24 advocate for the U.S. Environmental Protection Agency
25 to consider the cumulative impacts of chemicals within
26 their risk assessment process and quantify exposures
27 across pathways and populations; and (34) work with
28 members of the Federation to promote a reformed
29 TSCA that is consistent with goals of Registration,
30 Evaluation, Authorisation, and Restriction of Chemicals
31 (REACH), and (5) support the proactive restriction or
32 phasing-out of chemicals suspected of posing
33 significant health risks.
34

35 **RECOMMENDATION B:**

36
37 Your Reference Committee recommends that the
38 Recommendations in CSAPH 3 be adopted as amended
39 and the remainder of the report be filed.
40

41 **HOD ACTION:** CSAPH Report 3 adopted as amended and remainder of Report
42 filed.

43
44 **ADOPTED LANGUAGE:**

45 1. Policy H-135.901, “Addressing the Health Consequences of Microplastics in
46 Humans”

47 1. Our American Medical Association recognize the potential health risks
48 associated with plastics and microplastics and encourage increased research to

1 better understand the human health effects and environmental impacts of plastics
2 across their lifespan, including the chemicals used in plastic production.

3
4 **2. Our AMA supports the development of evidence-based guidelines for monitoring
5 and mitigating microplastic exposure in water, food, air, and other consumer
6 products.**

7
8 **3. Our AMA will collaborate with relevant stakeholders to promote public education
9 about microplastics, their sources, potential health risks, and possible strategies
10 for reducing exposure.**

11
12 **4. Our AMA supports policies to reduce plastic pollution, such as limits on single-
13 use plastics (for example plastic bags), incentivizing non-plastic alternatives such
14 as reusable bags, food containers, and packaging, incentivizing alternative
15 reformulations of synthetic plastics (such as bioplastics), and improving recycling
16 infrastructure and systems to better manage plastic waste.**

17
18 **2. Policy D-135.976, “Modernization of the Federal Toxic Substances Control Act
19 (TSCA) of 1976”**

20
21 **Our AMA will: (1) collaborate with relevant stakeholders to advocate for
22 modernizing the Toxic Substances Control Act (TSCA) to require chemical
23 manufacturers to provide adequate safety information on all chemicals and give
24 federal regulatory agencies reasonable authority to regulate hazardous
25 chemicals in order to protect the health of all individuals, especially vulnerable
26 populations; (2) support the public disclosure of chemical use, exposure and
27 hazard data in forms that are appropriate for use by medical practitioners,
28 workers, and the public; (3) advocate for the U.S. Environmental Protection
29 Agency to consider the cumulative impacts of chemicals within their risk
30 assessment process and quantify exposures across pathways and populations;
31 and (4) work with members of the Federation to promote a reformed TSCA that is
32 consistent with goals of Registration, Evaluation, Authorisation, and Restriction
33 of Chemicals (REACH), and (5) support the proactive restriction or phasing-out of
34 chemicals suspected of posing significant health risks.**

35
36
37 **The Council on Science and Public Health recommends that the following be adopted,
38 and the remainder of the report be filed.**

39
40 **1. That Policy H-135.901, “Addressing the Health Consequences of Microplastics in
41 Humans” be amended by addition and deletion to read as follows:**

42
43 **Addressing the Health Consequences of Plastics and Microplastics in Humans**

44
45 **1. Our American Medical Association recognize the potential health risks associated
46 with plastics and microplastics exposure and encourage increased research to better
47 understand the human health effects and environmental impacts of plastics across their
48 lifespan microplastics, including the chemicals used in plastic production.**

49

1 ~~2. Our AMA supports the development of respective specialty medical societies with~~
2 ~~subject matter expertise and federal and state public health agencies, including the~~
3 ~~Centers for Disease Control and Prevention (CDC) and the Environmental Protection~~
4 ~~Agency (EPA), to develop evidence-based guidelines for monitoring and mitigating~~
5 ~~microplastic exposure in water, food, air, and other consumer products.~~
6

7 3. Our AMA will collaborate with relevant stakeholders to promote public education about
8 microplastics, their sources, potential health risks, and possible strategies for reducing
9 exposure.

10
11 ~~4. Our AMA will study and report back with policy recommendations on ways to reduce~~
12 ~~plastic pollution and its impact on climate change and health, including but not limited to~~
13 ~~federal, state, and local taxes and limitations on the use of single use plastic consumer~~
14 ~~products and other types of plastic, interventions to reduce microplastics, and alternatives~~
15 ~~to plastic.~~
16

17 4. Our AMA supports policies to reduce plastic pollution, such as limits on single-use
18 plastics (for example plastic bags), incentivizing non-plastic alternatives such as reusable
19 bags, food containers, and packaging, incentivizing alternative reformulations of synthetic
20 plastics (such as bioplastics), and improving recycling infrastructure and systems to better
21 manage plastic waste.
22

23 2. That Policy D-135.976, "Modernization of the Federal Toxic Substances Control Act
24 (TSCA) of 1976" be amended by addition and deletion to read as follows:

25 Our AMA will: (1) collaborate with relevant stakeholders to advocate for modernizing the
26 Toxic Substances Control Act (TSCA) to require chemical manufacturers to provide
27 adequate safety information on all chemicals and give federal regulatory agencies
28 reasonable authority to regulate hazardous chemicals in order to protect the health of all
29 individuals, especially vulnerable populations; (2) support the public disclosure of chemical
30 use, exposure and hazard data in forms that are appropriate for use by medical
31 practitioners, workers, and the public; (3) encourage the U.S. Environmental Protection
32 Agency to consider the cumulative impacts of chemicals within their risk assessment
33 process and quantify exposures across pathways and populations; and (34) work with
34 members of the Federation to promote a reformed TSCA that is consistent with goals of
35 Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH), and (5)
36 support the proactive restriction or phasing-out of chemicals suspected of posing
37 significant health risks.
38

39 Your Reference Committee heard unanimously supportive testimony for this report noting
40 that the report discusses environmental and health impacts of plastic across the product
41 lifespan, as well as tangible strategies for reducing those impacts. A delegation proffered
42 an amendment to change the word "support" to "advocate for" in Policy D-135.976 noting
43 that the AMA needs to lead the way in advocating for better regulations on production, use
44 and disposal of plastic chemicals. Your Reference Committee agrees with this
45 amendment. Therefore, your Reference Committee recommends adoption of the
46 recommendations in CSAPH Report 3 as amended.

1 (12) RESOLUTION 902 - ADVOCATING FOR
2 IMPROVEMENTS IN SYSTEMS OF CARE FOR AUTISM
3

4 **RECOMMENDATION A:**
5

6 Your Reference Committee recommends Resolution
7 **902 be amended by addition and deletion to read as**
8 **follows:**
9

10 **RESOLVED, that our American Medical Association**
11 **advocate for peer reviewed, evidence-based guidance**
12 **for states on innovative health systems solutions to**
13 **reduce specific barriers to the diagnosis and treatment**
14 **of autism, including ~~and~~ complex care coordination in**
15 **the medical home by primary care team members**
16 **trained in the diagnosis and treatment of autism.**
17 **(Directive to Take Action)**
18

19 **RECOMMENDATION B:**
20

21 Your Reference Committee recommends that
22 Resolution 902 be **adopted as amended.**
23

24 **HOD ACTION: Resolution 902 be adopted as amended.**
25

26 **ADOPTED LANGUAGE:**

27 **RESOLVED, that our American Medical Association advocate for peer reviewed,**
28 **evidence-based guidance for states on innovative health systems solutions to**
29 **reduce specific barriers to the diagnosis and treatment of autism, including**
30 **complex care coordination in the medical home by primary care team members**
31 **trained in the diagnosis and treatment of autism.**
32

33
34 **RESOLVED, that our American Medical Association advocate for peer reviewed,**
35 **evidence-based guidance for states on innovative health systems solutions to reduce**
36 **specific barriers to the diagnosis of autism and complex care coordination in the medical**
37 **home by primary care team members trained in the diagnosis of autism. (Directive to Take**
38 **Action)**
39

40 The Reference Committee only heard supportive testimony regarding Resolution 902.
41 Speakers emphasized the importance of this policy. Members shared compelling personal
42 stories illustrating the challenges families face when navigating the diagnostic process
43 and coordinating care for children with autism. Members noted that these barriers to care
44 not only strain families financially and emotionally but also delay timely interventions that
45 are critical for positive outcomes. Resolution 902 was described as a meaningful step
46 toward reducing these burdens and ensuring equitable, comprehensive care for
47 individuals with autism and their families. An amendment was proffered to expand the
48 language of the resolution, which your Reference Committee agreed with and provided
49 additional editorial changes to include treatment, as testimony noted the importance of

1 treatment as well as diagnosis. Therefore, your Reference Committee recommends
2 Resolution 902 be adopted as amended.

3
4 (13) RESOLUTION 905 - STANDARDIZING BRAIN DEATH
5 POLICIES

6
7 **RECOMMENDATION A:**

8
9 **Your Reference Committee recommends the second**
10 **Resolve clause of Resolution 905 be amended by**
11 **addition and deletion to read as follows:**

12
13 **RESOLVED, that our AMA work with interested parties**
14 **to develop and disseminate model hospital policy for a**
15 **single, unified method of declaration or determination**
16 **of encourage and support legislative and regulatory**
17 **efforts to have one uniform set of standards for brain**
18 **death/death by neurologic criteria used throughout the**
19 **United States. (New HOD Policy)**

20
21 **RECOMMENDATION B:**

22
23 **Your Reference Committee recommends that**
24 **Resolution 905 be adopted as amended.**

25
26 **HOD ACTION: Resolution 905 be adopted as amended.**

27
28 **ADOPTED LANGUAGE:**

29 **RESOLVED, that our American Medical Association collaborate with appropriate**
30 **stakeholders to identify “accepted medical standards” for determination of brain**
31 **death/death by neurologic criteria (BD/DNC) as required by the Uniform**
32 **Determination of Death Act.**

33
34 **RESOLVED, that our AMA work with interested parties to develop and disseminate**
35 **model hospital policy for a single, unified method of declaration or determination**
36 **of brain death/death by neurologic criteria.**

37
38
39 **RESOLVED, that our American Medical Association collaborate with appropriate**
40 **stakeholders to identify “accepted medical standards” for determination of brain**
41 **death/death by neurologic criteria (BD/DNC) as required by the Uniform Determination of**
42 **Death Act (Directive to Take Action); and be it further**

43
44 **RESOLVED, that our AMA encourage and support legislative and regulatory efforts to**
45 **have one uniform set of standards for brain death/death by neurologic criteria used**
46 **throughout the United States. (New HOD Policy)**

47
48 **Your Reference Committee heard mixed testimony for Resolution 905 online and in**
49 **person. There was strong support for the first Resolve, with multiple delegations and**

1 individuals in support. Multiple delegations and an individual opposed the first Resolve.
2 The second Resolve was unanimously opposed as written, with parties expressing
3 concerns over inviting legislatures into decisions about the practice of medicine, slow
4 legislative process, and the need to retain flexibility around medical standards. One
5 delegation proposed an amendment that shifted the focus from legislative and regulatory
6 efforts to the development and dissemination of model hospital policy for a single, unified
7 method of declaration or determination of brain death/death by neurologic criteria. Multiple
8 delegations and an individual were in support of the amendment to the second Resolve.
9 One delegation also proposed adding a third resolve to expressly oppose legislative and
10 regulatory efforts to set BD/DNC standards – this received mixed testimony. One
11 delegation proposed referral, noting both the importance and complexity of the issue.
12 Finally, multiple individuals opposed the resolution in its entirety, whereas one individual
13 supported the first and second Resolves and proposed a third Resolve. Despite the mixed
14 testimony, there was a slight preference for the first Resolve and amended second
15 Resolve; therefore, your Reference Committee recommends adopting Resolution 905 as
16 amended.

17

18 (14) RESOLUTION 907 - IN-OFFICE DISPENSING OF
19 GENERIC MEDICATIONS

20

21 **RECOMMENDATION A:**

22

23 **Your Reference Committee recommends that the first**
24 **Resolve clause of Resolution 907 be amended by**
25 **addition and deletion to read as follows:**

26

27 **RESOLVED, that our AMA ~~consider developing~~ support**
28 **development of educational material for physicians**
29 **interested in dispensing generic medications to reduce**
30 **patient costs, improve access, and decrease**
31 **unnecessary prior authorization requirements**
32 **(Directive to Take Action); and be it further**

33

34 **RECOMMENDATION B:**

35

36 **Your Reference Committee recommends that**
37 **Resolution 907 be adopted as amended.**

38

39 **HOD ACTION: Resolution 907 be adopted as amended.**

40

41 **ADOPTED LANGUAGE:**

42 **RESOLVED, that our AMA support development of educational material for**
43 **physicians interested in dispensing generic medications to reduce patient costs,**
44 **improve access, and decrease unnecessary prior authorization requirements.**

45

46 **RESOLVED, that our AMA encourage medical associations in states with**
47 **restrictive dispensing laws to advocate for legislation allowing physicians to**
48 **dispense generic medications to patients.**

1 RESOLVED, that our American Medical Association consider developing educational
 2 material for physicians interested in dispensing generic medications to reduce patient
 3 costs, improve access, and decrease unnecessary prior authorization requirements
 4 (Directive to Take Action); and be it further

5
 6 RESOLVED, that our AMA encourage medical associations in states with restrictive
 7 dispensing laws to advocate for legislation allowing physicians to dispense generic
 8 medications to patients.

9
 10 Your Reference Committee heard varied testimony on this resolution. Largely there was
 11 support for this resolution noting the goal of improving access for patients to affordable
 12 medications. Further benefits were noted regarding how this work supports physician
 13 practice and patients, particularly in areas of pharmacy deserts. Opposition and calls for
 14 referral were rendered detailing the potential complexities and burden for physicians to
 15 implement a generic medication dispensing process as well as the many regulatory
 16 components from federal and state entities. Those opposed to referral highlighted the
 17 individualized, voluntary nature of the resolution, where this resolution is not requiring
 18 physicians to dispense if the practice is onerous and is more an olive branch of support
 19 with educational materials. An amendment was proffered to strengthen the first Resolve,
 20 and a second amendment was proffered to broaden the second Resolve. While your
 21 Reference Committee accepted the amendment to the first Resolve, we felt the
 22 amendment to the second Resolve broadened the policy beyond the intent and was
 23 redundant with current policy H-120.99, "Physician Dispensing." Therefore, your
 24 Reference Committee recommends adoption as amended.

25
 26 (15) RESOLUTION 909 - CLINICAL SIGNIFICANCE OF
 27 SLEEPINESS

28
 29 **RECOMMENDATION A:**

30
 31 **Your Reference Committee recommends that the first**
 32 **Resolve of Resolution 909 be amended by addition and**
 33 **deletion to read as follows:**

34
 35 **RESOLVED, that our AMA support the evaluation and**
 36 **management of sleepiness using validated clinical**
 37 **tools as a vital component of routine clinical services**
 38 **that are essential for patient safety and patient-centered**
 39 **care (New HOD Policy); and be it further**

40
 41 **RECOMMENDATION B:**

42
 43 **Your Reference Committee recommends that the**
 44 **second Resolve of Resolution 909 be amended by**
 45 **addition and deletion to read as follows:**

46
 47 **RESOLVED, that our AMA support initiatives that**
 48 **strengthen the clinical assessment ~~assess the impact~~**
 49 **of sleepiness and improve pathways to ~~and its~~**

1 ~~treatment on daytime functioning and quality of life in~~
2 ~~diverse populations.~~ (New HOD Policy)

3
4 **RECOMMENDATION C:**

5
6 Your Reference Committee recommends that
7 Resolution 909 be adopted as amended.

8
9 **HOD ACTION: Resolution 909 be adopted as amended.**

10
11 **ADOPTED LANGUAGE:**

12 **RESOLVED, that our AMA support the evaluation and management of sleepiness**
13 **using validated clinical tools as a vital component of routine clinical services.**

14
15 **RESOLVED, that our AMA support initiatives that strengthen the clinical**
16 **assessment of sleepiness and improve pathways to treatment.**

17
18
19 **RESOLVED, that our AMA support the evaluation and management of sleepiness as vital**
20 **clinical services that are essential for patient safety and patient-centered care (New HOD**
21 **Policy); and be it further**

22
23 **RESOLVED, that our AMA support initiatives that assess the impact of sleepiness and its**
24 **treatment on daytime functioning and quality of life in diverse populations. (New HOD**
25 **Policy)**

26
27 Your Reference Committee heard strong support for Resolution 909. One delegation
28 proposed amendments to both resolves to improve clarity of the author's original intent.
29 Specifically, in the first Resolve, language was added to highlight the importance of using
30 validated clinical tools for evaluation and management of sleepiness. In the second
31 Resolve, language was revised to highlight the need for initiatives that strengthen the
32 clinical assessment and improve treatment pathways. Testimony also noted that it was
33 important to expand beyond daytime sleepiness, and your Reference Committee agrees.
34 These amendments were unanimously supported. Therefore, your Reference Committee
35 recommends adoption of Resolution 909 as amended.

36
37 (16) RESOLUTION 911- SAFEGAUARDING NIH-FUNDED AND
38 OTHER WOMEN'S HEALTH RESEARCH IN PEER-
39 REVIEWED PUBLISHING

40
41 **RECOMMENDATION A:**

42
43 Your Reference Committee recommends that the first
44 Resolve clause of Resolution 911 be amended by
45 deletion to read as follows:

46
47 **RESOLVED, that our American Medical Association**
48 **supports the independence of scientific research**
49 **concerning women and underrepresented populations**

1 and the integrity of peer-reviewed medical journals
2 (New HOD Policy); and be it further
3

4 **RECOMMENDATION B:**

5
6 Your Reference Committee recommends that the
7 second Resolve clause of Resolution 911 be amended
8 by addition and deletion to read as follows:
9

10 **RESOLVED**, that our AMA advocates for continued
11 dissemination of rigorous women’s health research in
12 respected, independent journals and oppose measures
13 that could impede access to this research ~~silence or~~
14 ~~sideline these efforts~~ (Directive to Take Action); and be
15 it further
16

17 **RECOMMENDATION C:**

18
19 Your Reference Committee recommends that
20 Resolution 911 be adopted as amended.
21

22 **HOD ACTION:** Resolution 911 be adopted as amended.
23

24 **ADOPTED LANGUAGE:**

25 **RESOLVED**, that our American Medical Association supports the independence of
26 scientific research and the integrity of peer-reviewed medical journals; and be it
27 further
28

29 **RESOLVED**, that our AMA advocates for continued dissemination of rigorous
30 women’s health research in respected, independent journals and oppose measures
31 that could impede access to this research; and be it further
32

33 **RESOLVED**, that our AMA publicly supports the freedom of the National Institutes
34 of Health and other federally funded scientists and researchers to publish in
35 independent, peer-reviewed journals of their choosing.
36

37
38 **RESOLVED**, that our American Medical Association supports the independence of
39 scientific research concerning women and underrepresented populations and the integrity
40 of peer-reviewed medical journals (New HOD Policy); and be it further
41

42 **RESOLVED**, that our AMA advocates for continued dissemination of rigorous women’s
43 health research in respected, independent journals and oppose measures that could
44 silence or sideline these efforts (Directive to Take Action); and be it further
45

46 **RESOLVED**, that our AMA publicly supports the freedom of the National Institutes of
47 Health and other federally funded scientists and researchers to publish in independent,
48 peer-reviewed journals of their choosing. (Directive to Take Action)

1 Your Reference Committee heard testimony in support of this resolution, noting the critical
2 time for reinforcing the freedom and integrity of researchers to pursue and disseminate
3 evidence. Further, testimony highlighted the importance of research to support evidence-
4 based, high-quality practice. While the testimony was supportive of the intent,
5 amendments were proffered to expand resolve 1 to all scientific research and temper
6 inflammatory language in resolve 2. Your Reference Committee agreed with these
7 amendments and recommends adoption as amended.
8

9 (17) RESOLUTION 912 - INCREASING ACCESS THROUGH
10 FEDERATED HEALTHCARE DATA ARCHITECTURE
11

12 **RECOMMENDATION A:**
13

14 Your Reference Committee recommends that
15 Resolution 912 be amended by addition to read as
16 follows:
17

18 **RESOLVED**, that our American Medical Association
19 study federated and other data architecture to evaluate
20 its utility in expanding access to large de-identified
21 healthcare datasets across institutions with the aims of
22 enhancing interoperability through multi-center
23 collaboration, preserving confidentiality by avoiding
24 centralization of PHI, and accelerating ethical research
25 and precision care. (Directive to Take Action)
26

27 **RECOMMENDATION B:**
28

29 Your Reference Committee recommends that
30 Resolution 912 be adopted as amended.
31

32 **HOD ACTION:** Resolution 912 be adopted as amended.
33

34 **ADOPTED LANGUAGE:**
35

36 **RESOLVED**, that our American Medical Association study federated and other
37 data architecture to evaluate its utility in expanding access to large de-identified
38 healthcare datasets across institutions with the aims of enhancing interoperability
39 through multi-center collaboration, preserving confidentiality by avoiding
40 centralization of PHI, and accelerating ethical research and precision care.
41

42 **RESOLVED**, that our American Medical Association study federated data architecture to
43 evaluate its utility in expanding access to large de-identified healthcare datasets across
44 institutions with the aims of enhancing interoperability through multi-center collaboration,
45 preserving confidentiality by avoiding centralization of PHI, and accelerating ethical
46 research and precision care. (Directive to Take Action)

1 Your Reference Committee heard testimony that was supportive of this resolution.
2 Testimony noted the need for broader multi-center health care research collaborations
3 and federated data systems, while improving patient data safety by avoiding the
4 centralization of protected health information to accelerate ethical research and precision
5 care. It was noted that it is critical to understand why other large-scale data coordination
6 strategies have failed to advance despite decades of interest. An amendment was
7 suggested to broaden this study beyond federated data architecture to also include other
8 data architecture. Your Reference Committee agrees and recommends adoption of this
9 resolution as amended.

10
11 (18) RESOLUTION 933 - ADDRESSING GAPS IN NATIONAL
12 HEALTHCARE SAFETY NETWORK (NHSN) DATA
13 QUALITY

14
15 **RECOMMENDATION A:**

16
17 **Your Reference Committee recommends the second**
18 **Resolve clause of Resolution 933 be amended by**
19 **addition and deletion to read as follows:**

20
21 **RESOLVED, that our AMA advocate for the CDC to**
22 **establish ~~and enforce~~ consistent NHSN data collection**
23 **methods for surgical site infection (SSI) surveillance**
24 **across hospitals and audit hospital NHSN data quality**
25 **for SSI regardless of hospital performance status.**
26 **(Directive to Take Action)**

27
28 **RECOMMENDATION B:**

29
30 **Your Reference Committee recommends that**
31 **Resolution 933 be adopted as amended.**

32
33 **HOD ACTION: Resolution 933 be adopted as amended.**

34
35 **ADOPTED LANGUAGE:**

36 **RESOLVED, that our American Medical Association advocate for the CDC to use**
37 **its January 2024 definition of Surgical Site Infection (SSI) in the National**
38 **Healthcare Safety Network (NHSN), and require documented clinical impression of**
39 **an SSI; and be it further**

40
41 **RESOLVED, that our AMA advocate for the CDC to establish consistent NHSN**
42 **data collection methods for surgical site infection (SSI) surveillance across**
43 **hospitals and audit hospital NHSN data quality for SSI regardless of hospital**
44 **performance status.**

45
46
47 **RESOLVED, that our American Medical Association advocate for the CDC to use its**
48 **January 2024 definition of Surgical Site Infection (SSI) in the National Healthcare Safety**

1 Network (NHSN), and require documented clinical impression of an SSI (Directive to Take
2 Action); and be it further

3
4 RESOLVED, that our AMA advocate for the CDC to establish and enforce consistent
5 NHSN data collection methods across hospitals and audit hospital NHSN data quality
6 regardless of hospital performance status. (Directive to Take Action)

7
8 Your Reference Committee heard limited but mostly supportive testimony on Resolution
9 933. One delegation in support noted the importance of having an acceptable definition of
10 surgical site infection. Another delegation noted that while they support the first resolved
11 clause, the second clause could be misinterpreted as endorsing sweeping new data
12 mandates that lack clear evidence of benefit and could introduce infrastructure burdens
13 without improving patient care. Your Reference Committee agrees with this issue and has
14 proffered an amendment to address this concern by narrowing the scope of the second
15 Resolved clause to surgical site infections. Therefore, your Reference Committee
16 recommends Resolution 933 be adopted as amended.

17
18 (19) RESOLUTION 935 - ENHANCING HEALTHCARE
19 SYSTEM PREPAREDNESS TO ADDRESS VETERAN-
20 SPECIFIC HEALTH DISPARITIES

21
22 **RECOMMENDATION A:**

23
24 Your Reference Committee recommends that the
25 second Resolve in Resolution 935 be amended by
26 addition and deletion to read as follows:

27
28 RESOLVED, that our AMA actively advocate with
29 medical education accrediting bodies to ~~require~~
30 encourage medical schools, residency programs, and
31 providers of continuing medical education providers to
32 incorporate training on military service-related health
33 conditions, occupational exposure assessment, and
34 Veteran-specific screening protocols into curricula in
35 order and ~~licensure requirements~~ to improve
36 preparedness of the healthcare workforce (Directive to
37 Take Action); and be it further

38
39 **RECOMMENDATION B:**

40
41 Your Reference Committee recommends that the
42 remainder of Resolution 935 be adopted as amended.

43
44 **HOD ACTION:** Resolution 935 be adopted as amended.

45
46 **ADOPTED LANGUAGE:**

47 RESOLVED, that our American Medical Association actively advocate for federal,
48 state, and local legislation and regulatory action requiring healthcare systems to
49 develop and implement standardized protocols for identifying Veterans in patient

1 populations, including documenting military service history (deployment locations
2 and occupational exposures), and stratifying quality and safety data by Veteran
3 status, in accordance with Joint Commission accreditation standards.
4

5 **RESOLVED**, that our AMA actively advocate with medical education accrediting
6 bodies to encourage medical schools, residency programs, and providers of
7 continuing medical education to incorporate training on military service-related
8 health conditions, occupational exposure assessment, and Veteran-specific
9 screening protocols into curricula in order to improve preparedness of the
10 healthcare workforce.

11
12 **RESOLVED**, that our AMA advocate for, and facilitate, robust collaboration with
13 Veterans Service Organizations, medical specialty societies, and state public health
14 authorities to develop, disseminate, and promote adoption of evidence-based
15 clinical guidelines for Veteran-specific health conditions.
16

17 **RESOLVED**, that our AMA advocate for inclusion of Veteran health considerations
18 in all relevant health equity initiatives, community health needs assessments, and
19 population health frameworks, at all levels of government, recognizing that
20 systematic identification, documentation, and management of service-connected
21 conditions are critical to addressing health disparities for those who have served.
22

23
24 **RESOLVED**, that our American Medical Association actively advocate for federal, state,
25 and local legislation and regulatory action requiring healthcare systems to develop and
26 implement standardized protocols for identifying Veterans in patient populations, including
27 documenting military service history (deployment locations and occupational exposures),
28 and stratifying quality and safety data by Veteran status, in accordance with Joint
29 Commission accreditation standards (Directive to Take Action); and be it further
30

31 **RESOLVED**, that our AMA actively advocate with medical education accrediting bodies to
32 require medical schools, residency programs, and continuing medical education providers
33 to incorporate training on military service-related health conditions, occupational exposure
34 assessment, and Veteran-specific screening protocols into curricula and licensure
35 requirements to improve preparedness of the healthcare workforce (Directive to Take
36 Action); and be it further
37

38 **RESOLVED**, that our AMA advocate for, and facilitate, robust collaboration with Veterans
39 Service Organizations, medical specialty societies, and state public health authorities to
40 develop, disseminate, and promote adoption of evidence-based clinical guidelines for
41 Veteran-specific health conditions (Directive to Take Action); and be it further
42

43 **RESOLVED**, that our AMA advocate for inclusion of Veteran health considerations in all
44 relevant health equity initiatives, community health needs assessments, and population
45 health frameworks, at all levels of government, recognizing that systematic identification,
46 documentation, and management of service-connected conditions are critical to
47 addressing health disparities for those who have served. (Directive to Take Action)

1 Your Reference Committee heard near-unanimous support for this resolution. Many
2 delegations and individuals testified to the importance of veterans' health as an issue that
3 should be addressed similarly to social determinants of health (SDOH). One delegation
4 noted that many veterans seek care outside the Veterans Health Administration (VA),
5 either due to access issues or a preference for community-based care. They emphasized
6 that physicians practicing outside the VA need additional education and awareness to
7 screen for veterans' status, which is associated with multiple health conditions. Your
8 Council on Medical Education testified in opposition to the second Resolve, which
9 originally called for the AMA to advocate for mandatory medical school and licensure
10 requirements. This recommendation conflicts with existing policy H-300.953, which states
11 that the AMA and other medical organizations do not have the authority or responsibility
12 to set standards and curricula for continuing medical education (CME), and that state
13 medical societies should amend their own CME mandates. Further, testimony supported
14 the view that mandates could have unintended consequences, and that the AMA should
15 prioritize further education and advocacy rather than requiring new competencies. In
16 response, your Reference Committee proposed an amendment to remove the mandate in
17 the second Resolve. Therefore, your Reference Committee recommends that Resolution
18 935 be adopted as amended.

RECOMMENDED FOR ADOPTION IN LIEU OF

1
2
3 (20) RESOLUTION 931 - PRESERVING EVIDENCE-BASED,
4 EQUITABLE GROOMING STANDARDS IN MILITARY
5 SERVICE
6

7 **RECOMMENDATION:**
8

9 **Your Reference Committee recommends Alternate**
10 **Resolution 931 be adopted in lieu of Resolution 931.**
11

12 **PRESERVING EVIDENCE-BASED, EQUITABLE**
13 **GROOMING STANDARDS IN THE UNIFORMED**
14 **SERVICES.**
15

16 **RESOLVED, that our American Medical Association**
17 **advocate against Uniformed Services policy changes**
18 **that restrict or eliminate evidence-based, medically**
19 **necessary shaving waivers for service members, and**
20 **oppose administrative or physical evaluation board**
21 **separation on this basis when service members**
22 **otherwise meet qualifications for continued service**
23 **(Directive to Take Action); and be it further**
24

25 **RESOLVED, that our AMA urge the Uniformed Services**
26 **to implement any changes to shaving waiver policy**
27 **through an evidence-based and transparent process**
28 **that incorporates input from Uniformed Services**
29 **dermatologists, occupational health experts, affected**
30 **service members, and other interested parties with**
31 **relevant expertise (Directive to Take Action); and be it**
32 **further**
33

34 **RESOLVED, that our AMA advocate for consistent and**
35 **equitable shaving waiver policies across all Uniformed**
36 **Services branches, including standardized criteria,**
37 **clear re-evaluation intervals and portability of waivers**
38 **across duty stations (Directive to Take Action); and be**
39 **it further**
40

41 **RESOLVED, that our AMA urge the Uniformed Services**
42 **to authorize permanent shaving waivers for service**
43 **members with severe or refractory pseudofolliculitis**
44 **barbae, especially those who have already received**
45 **Uniformed Services dermatologist recommendations**
46 **for permanent waivers and are unresponsive to**
47 **optimized medical therapy, and to extend this option**
48 **consistently across all service branches (Directive to**
49 **Take Action); and be it further**

1 **RESOLVED**, that our AMA support ongoing research on
2 pseudofolliculitis barbae and related dermatologic
3 conditions, including medical management, equity
4 impacts of grooming practices, and evidence-based
5 approaches to accommodations within the Uniformed
6 Services. (New HOD Policy)
7

8 **HOD ACTION: Alternate Resolution 931 be adopted in lieu of Resolution 931.**
9

10 **ADOPTED LANGUAGE:**

11 **PRESERVING EVIDENCE-BASED, EQUITABLE GROOMING STANDARDS IN THE**
12 **UNIFORMED SERVICES.**

13
14 **RESOLVED**, that our American Medical Association advocate against Uniformed
15 Services policy changes that restrict or eliminate evidence-based, medically
16 necessary shaving waivers for service members, and oppose administrative or
17 physical evaluation board separation on this basis when service members
18 otherwise meet qualifications for continued service;
19

20 **RESOLVED**, that our AMA urge the Uniformed Services to implement any changes
21 to shaving waiver policy through an evidence-based and transparent process that
22 incorporates input from Uniformed Services dermatologists, occupational health
23 experts, affected service members, and other interested parties with relevant
24 expertise;
25

26 **RESOLVED**, that our AMA advocate for consistent and equitable shaving waiver
27 policies across all Uniformed Services branches, including standardized criteria,
28 clear re-evaluation intervals and portability of waivers across duty stations;
29

30 **RESOLVED**, that our AMA urge the Uniformed Services to authorize permanent
31 shaving waivers for service members with severe or refractory pseudofolliculitis
32 barbae, especially those who have already received Uniformed Services
33 dermatologist recommendations for permanent waivers and are unresponsive to
34 optimized medical therapy, and to extend this option consistently across all
35 service branches;
36

37 **RESOLVED**, that our AMA support ongoing research on pseudofolliculitis barbae
38 and related dermatologic conditions, including medical management, equity
39 impacts of grooming practices, and evidence-based approaches to
40 accommodations within the Uniformed Services.
41

42
43 **RESOLVED**, that our American Medical Association advocate against Department of War
44 policy changes that restrict or eliminate evidence-based, medically necessary shaving
45 waivers for service members, and oppose administrative or physical evaluation board
46 separation on this basis when service members otherwise meet qualifications for
47 continued service (Directive to Take Action); and be it further
48

1 RESOLVED, that our AMA urge the Department of War to implement any changes to
2 shaving waiver policy through an evidence-based and transparent process that
3 incorporates input from military dermatologists, occupational health experts, affected
4 service members, and other interested parties with relevant expertise (Directive to Take
5 Action); and be it further

6
7 RESOLVED, that our AMA advocate for consistent and equitable shaving waiver policies
8 across all military service branches, including standardized criteria, clear re-evaluation
9 intervals and portability of waivers across duty stations (Directive to Take Action); and be
10 it further

11
12 RESOLVED, that our AMA urge the Department of War to authorize permanent shaving
13 waivers for service members with severe or refractory pseudofolliculitis barbae, especially
14 those who have already received military dermatologist recommendations for permanent
15 waivers and are unresponsive to optimized medical therapy, and to extend this option
16 consistently across all service branches (Directive to Take Action); and be it further

17
18 RESOLVED, that our AMA support ongoing research on pseudofolliculitis barbae and
19 related dermatologic conditions, including medical management, equity impacts of
20 grooming practices, and evidence-based approaches to accommodations within the
21 Armed Forces. (New HOD Policy)

22
23 Your Reference Committee heard testimony in strong support for Resolution 931 from
24 multiple delegations and sections. One delegation proposed an amendment to expand
25 language in all resolves to include the Public Health Service Commissioned Corps and
26 the National Oceanic and Atmospheric Administration Commissioned Officer Corps. The
27 majority of sections and delegations supported the amendment and in accordance the
28 author proposed a title change to ensure alignment, so your Reference Committee
29 recommends adopting Alternate Resolution 931 in lieu of Resolution 931.

RECOMMENDED FOR REFERRAL

(21) RESOLUTION 906 - RETHINKING THE MEDICARE ANNUAL WELLNESS VISIT

RECOMMENDATION:

Your Reference Committee recommends that Resolution 906 be referred.

HOD ACTION: Resolution 909 be referred.

RESOLVED, that our American Medical Association advocate for a thoughtful reevaluation of the Medicare annual wellness visit and consider replacing it with an annual comprehensive examination that would integrate preventive care services, a thorough physical exam, and the management of acute or chronic health conditions. (Directive to Take Action)

Your Reference Committee heard mixed testimony on this item. One delegation noted that current evidence supports periodic provision of many services, but it doesn't include a comprehensive examination. One delegation in support of adoption noted that the Medicare Wellness Visit (AWV) has proven to be cumbersome, with little benefits from its implementation and that a comprehensive physical would be better utilization of physician time. A delegation and multiple individuals noted that while the AWV might warrant scrutiny, available evidence does not indicate that there is a health benefit to performing routine, complete exams and therefore proposed referral of this item for study. Given the mixed testimony and the complexity of this issue, your Reference Committee recommends that Resolution 906 be referred.

(22) RESOLUTION 917 - URGING COMPREHENSIVE RESEARCH AND SAFETY TESTING OF INDUSTRY-ENGINEERED FOOD ADDITIVES (IEFAS), INCLUDING HIGH FRUCTOSE CORN SYRUP

RECOMMENDATION:

Your Reference Committee recommends that Resolution 917 be referred.

HOD ACTION: Resolution 917 be referred.

RESOLVED, that our American Medical Association supports stronger safety protocols and regulatory oversight of food additives, to protect the health and well-being of the American public (New HOD Policy); and be it further

1 RESOLVED, that our AMA advocate federal policies requiring comprehensive scientific
2 research and safety testing of industry-engineered food additives, including HFCS and
3 other similar substances, prior to their approval by federal regulators for use in the food
4 supply. (Directive to Take Action)
5

6 The Reference Committee heard mixed testimony on Resolution 917 calling for
7 comprehensive research and safety testing of industry-engineered food additives (IEFAs),
8 including high fructose corn syrup. Testimony reflected broad concern about the potential
9 health impacts of these additives and emphasized the need for stronger regulatory
10 oversight. However, the issue was acknowledged as complex, involving multiple
11 stakeholders and intersecting with broader food policy considerations. Several speakers
12 noted that while the intent of the resolution is important, more information is needed to
13 fully understand the implications and scope of such research and regulation. It was also
14 highlighted that a CSAPH report on food subsidies will be presented at the upcoming
15 Annual Meeting, which will highlight food additives including high fructose corn syrup
16 related policy discussions. However, there was concern that this would not sufficiently
17 address issues in this resolution. Therefore, your Reference Committee recommends that
18 Resolution 917 be referred.
19

20 (23) RESOLUTION 918 - REMOVE OUTDATED BARRIERS TO
21 GENETIC TESTING
22

23 **RECOMMENDATION:**

24
25 **Your Reference Committee recommends that**
26 **Resolution 918 be referred.**
27

28 **HOD ACTION: Resolution 918 be referred.**

30
31 RESOLVED, that our American Medical Association advocate for federal and state
32 legislation to remove requirements for separate written consent for genetic or genomic
33 testing, and to eliminate unnecessary restrictions on sharing test result records with the
34 treating team of providers, while preserving essential patient protections, including
35 safeguards against discrimination by insurance companies (Directive to Take Action); and
36 be it further
37

38 RESOLVED, that our AMA advocate for changes to laws nationwide in the states that
39 continue to impose barriers to genetic or genomic testing in the form of written consent
40 requirements in Massachusetts, Michigan, Nebraska, New York, South Dakota, and that
41 our AMA report on the status of this resolution at the 2026 Annual Meeting. (Directive to
42 Take Action)

1 Your Reference Committee heard generally mixed testimony on this resolution. Some
2 members in support of the resolution noted that genetic testing is often ordered by Family
3 Physicians and can create barriers to practice. Others in opposition noted that the request
4 to remove unnecessary restrictions on sharing test results is redundant due to all testing
5 results being housed in the electronic medical record. Two delegations requested referral
6 for study due to the complexity of genetic testing, informed consent, and variable policy
7 state by state. Your Reference Committee agrees with the complexity noted, and
8 therefore, recommends that Resolution 918 be referred.

9
10 (24) RESOLUTION 921 - PRIORITIZING DESPRESCRIBING
11 IN SENIORS

12
13 **RECOMMENDATION:**

14
15 **Your Reference Committee recommends that**
16 **Resolution 921 be referred.**

17
18 **HOD ACTION: Resolution 921 be referred.**

19
20
21 RESOLVED, that our American Medical Association declare that deprescribing, the
22 proactive and systematic identification and discontinuation of medications with potential
23 risk greater than potential benefits, is a medical priority in the management of senior
24 patients and advocate for the integration of deprescribing as a standard component of
25 high-quality prescribing practices (Directive to Take Action); and be it further

26
27 RESOLVED, that our AMA advocate for the development of educational initiatives and
28 clinical decision support tools to facilitate safe and effective deprescribing in electronic
29 health records (Directive to Take Action); and be it further

30
31 RESOLVED, that our AMA call for research and policy efforts to address barriers for
32 implementation of deprescribing in routine medical care (Directive to Take Action); and be
33 it further

34
35 RESOLVED, that our AMA advocate for all insurers to reimburse deprescribing activities
36 (Directive to Take Action); and be it further

37
38 RESOLVED, that our AMA shall report back on the status of deprescribing to the House
39 of Delegates at A-26 and yearly thereafter, with appropriate metrics to address potential
40 barriers and to guide further advocacy, until it has become implemented as a mainstream
41 component of health care. (Directive to Take Action)

42
43 The Reference Committee heard mixed testimony from Resolution 921 on the topic of
44 deprescribing. Several speakers emphasized that deprescribing should be viewed not
45 merely as an extension of medication reconciliation but as a broader strategy for
46 medication optimization. They highlighted its potential to improve patient safety and
47 reduce costs. However, testimony also reflected significant concern about unintended
48 consequences, particularly around proposals to support reimbursement for deprescribing
49 activities. Some members cautioned that introducing reimbursement mechanisms could

1 inadvertently incentivize inappropriate deprescribing or create administrative burdens
2 without clear evidence of improved outcomes. Others noted the need for safeguards to
3 ensure that deprescribing decisions remain clinically driven and patient centered. Overall,
4 with these concerns in mind, multiple delegations called for referral of this item to further
5 understand the implications. Therefore, your Reference Committee recommends
6 Resolution 921 be referred.

7
8 (25) RESOLUTION 927 - BATTLEFIELD ACUPUNCTURE - AN
9 EDUCATIONAL CALL TO ARMS

10
11 **RECOMMENDATION:**

12
13 **Your Reference Committee recommends that**
14 **Resolution 927 be referred.**

15
16 **HOD ACTION: Resolution 927 be referred.**

17
18
19 RESOLVED, that our American Medical Association encourage greater awareness of
20 and/or instruction in the use of Battlefield Acupuncture as a quick, safe, and effective
21 means to treat acute and chronic pain in patients, given its exceptional safety record, high
22 level of reproducibility, and ability to be administered in an extremely cost-effective
23 manner, without concerns for drug-drug interactions or dependence on narcotic
24 analgesics. (New HOD Policy)

25
26 Your Reference Committee heard mixed testimony on this resolution. Supporters
27 emphasized the effectiveness of battlefield acupuncture (BFA), highlighting both its
28 treatment efficacy and cost benefits. They also cited extensive evidence of BFA's utility
29 within the Veterans Health Administration (VA), referencing over 95 studies that
30 demonstrate treatment effectiveness. In contrast, many of the sections and individual
31 members, including your Council on Science and Public Health, were against adoption.
32 Concerns centered on a lack of evidence for BFA's effectiveness outside the VA and the
33 overall absence of rigorous studies that adequately controlled for bias and placebo effect.
34 Additionally, a delegation noted that AMA policy typically does not endorse specific clinical
35 procedures. Your Reference Committee recognizes the positive intentions of the
36 resolution's authors and appreciates that all physicians seek effective treatments for
37 chronic pain; however, the lack of broader evidence remains a concern. Therefore, your
38 Reference Committee recommends that Resolution 927 be referred.

1 (26) RESOLUTION 930 - ESTABLISHING FIRE RISK
2 STANDARDS FOR CIVILIAN AND NON-INDUSTRIAL
3 CLOTHING
4

5 **RECOMMENDATION:**
6

7 **Your Reference Committee recommends that**
8 **Resolution 930 be referred.**
9

10 **HOD ACTION: Resolution 930 be referred.**
11

12
13 RESOLVED, that our American Medical Association study the flammability of and fire-
14 resistant treatments for consumer clothing materials and their potential public health
15 benefits (Directive to Take Action); and be it further
16

17 RESOLVED, that our AMA study the value of updated flammability risk standards that
18 incorporate modern textile compositions and their associated fire risks (Directive to Take
19 Action); and be it further
20

21 RESOLVED, that our AMA encourage the Consumer Product Safety Commission (CPSC)
22 and relevant regulatory bodies to update and enforce stricter fire safety labeling and
23 testing requirements for civilian clothing and support educating the public on flammability
24 risk on apparel labels. (New HOD Policy)

25 Your Reference Committee heard mixed testimony. One delegation was supportive of
26 resolves one and two but proposed removing the third resolve noting concerns about the
27 safety of classes of chemicals used as fire retardant and the need for more study. In
28 contrast, a different delegation only supported resolve three. One section supported all
29 the original resolves and proposed the addition of a fourth resolve that called for the
30 Consumer Product Safety Commission, the National Institute of Standards and
31 Technology, and the National Institute for Occupational Safety and Health, to evaluate the
32 potential dermatologic impacts of flame-resistant and chemically treated textiles and to
33 consider labeling standards that disclose chemical treatments and known skin sensitizers
34 used in textile manufacturing. Finally, one individual and one delegation called for referral
35 for study. Given the lack of consensus and multiple calls for study, your Reference
36 Committee recommends that Resolution 930 be referred.

RECOMMENDED FOR REFERRAL FOR DECISION

(27) RESOLUTION 919 - STRENGTHENING TRUST THROUGH AMA-BASED LEADERSHIP FOR EVIDENCE-BASED VACCINES (STABLE VACCINES)
RESOLUTION 925 - EVIDENCE-BASED VACCINE AND PREVENTIVE SERVICES RECOMMENDATION

RECOMMENDATION:

Your Reference Committee recommends that Alternate Resolution 919 be referred for decision.

HOD ACTION: Resolution 919 be referred for decision.

RESOLVED, that our American Medical Association will serve as a convener of key stakeholders to advance science-based vaccine recommendations (Directive to Take Action); and be it further

RESOLVED, that our AMA will establish itself as a trusted, centralized source and public-facing megaphone for science-based vaccine guidance (Directive to Take Action); and be it further

RESOLVED, that our AMA will contribute expertise and funding, as appropriate, to advance the mission of coordinating and promoting scientifically grounded and reliable vaccine guidance. (Directive to Take Action)

RESOLVED, that our American Medical Association will replace all references in our policies to the Advisory Committee on Immunization Practices (ACIP) and the U.S. Preventive Services Task Force (USPSTF) with “current evidence-based recommendations developed by authoritative medical entities” (Directive to Take Action); and be it further

RESOLVED, that our AMA will study options for replacing, to the extent possible, the ACIP and USPSTF at the earliest possible time with a national entity which will develop and publish credible evidence-based recommendations for vaccines and preventive services. (Directive to Take Action)

Your Reference Committee heard mixed testimony on alternate Resolution 919. There was broad recognition that it is imperative for physicians and the public to have evidence-based guidance on preventive services, including vaccines, that they can rely on. It is also clear based on testimony that this is of urgent concern given the changes made to the ACIP as well as the possible changes to the USPSTF. While some who testified supported alternate Resolution 919 citing the need for a transparent process that can best serve patients, others noted that efforts are already underway in response to the emergency resolution adopted by the House of Delegates at A-25, and there is no need to unnecessarily impede the AMA’s ability to act. There was also concern regarding the framing of the fourth Resolve clause calling for a study of options to replace the ACIP and

1 USPSTF. It was noted by several who testified that the goal should be restoration of these
2 evidence-based bodies and not replacement. Others who testified noted that we should
3 not be looking back but rather looking for an optimal way forward. A number of delegations
4 actively working in this space called for referral of this resolution for study with a report
5 back at A-26. Given work already underway by the AMA and the need for timely action
6 around options for convening and the development of evidence-based recommendations
7 going forward, your Reference Committee believes that alternate Resolution 919 should
8 be referred for decision.

RECOMMENDED FOR NOT ADOPTION

(28) RESOLUTION 904 - SUPPORTING CERTIFICATION OF
THE PUBLIC HEALTH WORKFORCE

RECOMMENDATION:

**Your Reference Committee recommends that
Resolution 904 be not adopted.**

HOD ACTION: Resolution 904 not adopted.

RESOLVED, that our American Medical Association support and endorse the Certified in Public Health (CPH) credential as a valuable certification for public health professionals (New HOD Policy); and be it further

RESOLVED, that our AMA encourage physicians engaged in public health practice to pursue and advocate for the CPH certification. (New HOD Policy)

Your Reference Committee heard unanimous testimony in opposition to this resolution. Multiple individuals and delegations/sections noted that while they support the education and training of both physicians and non-physicians in public health, adoption of this resolution by the AMA will confuse physicians and sets up an endorsement of training that includes non-physicians which is not within the primary scope of the AMA. Therefore, your Reference Committee recommends that Resolution 904 be not adopted.

(29) RESOLUTION 908 - SUPPORT OF ACCESS TO INSULIN-
DETEMIR

RECOMMENDATION:

**Your Reference Committee recommends that
Resolution 908 be not adopted.**

HOD ACTION: Resolution 908 not adopted.

RESOLVED, that our American Medical Association support the designation of insulin-detemir as a drug in shortage to expedite FDA review and approval of biosimilar versions while the reference product remains available globally (New HOD Policy); and be it further

RESOLVED, that our AMA support allowing some of the funding allocated to the Special Diabetes Program to be used to incentivize domestic manufacturing of insulin, including insulin-detemir (New HOD Policy); and be it further

RESOLVED, that our AMA encourages the FDA to consider classifying insulin-detemir as an over-the-counter medication to expand access and affordability for individuals with diabetes (New HOD Policy); and be it further

1
2 RESOLVED, that our American Medical Association lobby Congress to pass legislation,
3 or a similarly effective action, to accomplish the goals outlined in this resolution. (Directive
4 to Take Action)
5

6 Your Reference Committee heard testimony that access to insulin and diabetes
7 treatments is critical to their patients. However, there was opposition to each of the
8 resolves for different reasons. First, there was significant opposition to advocating for
9 insulin detemir to be deemed an over-the-counter product due to the potential for adverse
10 events as a high-risk medication. Testimony was additionally heard in opposition to
11 adjustments to the Special Diabetes Program funding which may hinder research and
12 work in Type 1 Diabetes and underserved tribal populations. Finally, there was concern
13 on amendments proffered to advocating for a drug to be deemed a drug shortage outside
14 of the FDA regulated pathway. It was noted that new long-acting biosimilar insulin is soon
15 to be on the market at a lower cost to minimize the challenge of insulin detemir being
16 pulled from the market. Therefore, your Reference Committee recommends that this
17 resolution be not adopted.

1 **RECOMMENDED FOR REAFFIRMATION IN LIEU OF**

2
3 (30) RESOLUTION 903 - NITROUS OXIDE INHALANT ABUSE

4
5 **RECOMMENDATION:**

6
7 **Your Reference Committee recommends that policy D-**
8 **95.951 be reaffirmed in lieu of Resolution 903.**

9
10 **HOD ACTION: Resolution 903 adopted as amended with a title change.**

11
12 **ADOPTED LANGUAGE:**

13 **NITROUS OXIDE INHALANT MISUSE**

14 **RESOLVED, that our American Medical Association encourage and support the**
15 **regulation of the branding of nitrous oxide canisters by U.S. Food and Drug**
16 **Administration.**

17
18
19 **RESOLVED, that our American Medical Association encourage and support the regulation**
20 **of the branding of nitrous oxide canisters by U.S. Food and Drug Administration. (New**
21 **HOD Policy)**

22
23 Your Reference Committee heard limited and mixed testimony on this resolution. One
24 delegation agreed with reaffirmation due to the similarity of existing policy D-95.951.
25 Another delegation supported the original resolution and disagreed with reaffirmation due
26 to the coercive branding employed by nitrous oxide manufacturers that policy D-95.951
27 does not cover. The authors proffered an amendment to replace the term “branding” with
28 “labeling”. However, despite this effort, there continues to be limited clarity around what
29 the regulation would actually entail on the label related to nitrous oxide inhalant misuse
30 and a lack of clarity of what the Resolve would actually accomplish. Therefore, your
31 Reference Committee recommends that policy D-95.951 be reaffirmed in lieu of
32 Resolution 903.

1 This concludes the report of Reference Committee K. I would like to thank Jade Anderson,
2 MD, Shanna Combs, MD, Oluwasegun Paul Emenogu, MD, Beulette Hooks, MD, Charles
3 Lopresto, DO, Arlene Seid, MD, MPH, and all those who testified before the Committee,
4 as well as our AMA staff Jennie Jarrett, Katlyn Dillane, Jane Sachs, and Mary Soliman.

Jade A. Anderson, MD
Radiological Society of North America

Beulette Hooks, MD
American Academy of Family
Physicians

Shanna M. Combs, MD (Alternate)
Texas

Charles Lopresto, DO
Medical Society of the State of New
York

Oluwasegun Paul Emenogu, MD
Resident and Fellow Section

Arlene Seid, MD, MPH
American Association of Public Health
Physicians

Samuel Huang, MD
California
Chair

Amendments

If you wish to propose an amendment to an item of business, scan the QR code below:



<https://forms.office.com/r/13Y1p3bQg9>

This same form can also be found by clicking here: [Submit New Amendment](#)